Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

UBS maintains sell on Medtronic stock, raises price target

EditorAhmed Abdulazez Abdulkadir
Published 24/05/2024, 10:42
© Shutterstock
MDT
-

On Friday, UBS maintained its Sell rating on Medtronic , Inc. (NYSE:MDT) but slightly increased the price target to $76.00 from $75.00. The firm recognized Medtronic's solid performance in the fourth fiscal quarter of 2024, highlighting the improving momentum in key business segments.

Medtronic's sales and earnings per share (EPS) exceeded expectations, particularly driven by the U.S. launch of the new 780G automated insulin delivery system, which represents 8% of the company's total fiscal year 2024 sales.

Despite the positive results, UBS expressed caution regarding the sustainability of the growth, specifically within the Diabetes segment. The firm pointed out that there were areas of weakness, such as below-market growth in Ablation Solutions.

Additionally, Medtronic's management has identified several headwinds for the fiscal year 2025, including persistent inflation, increased research and development (R&D) expenditures, and a higher tax rate.

UBS acknowledged Medtronic's strong quarterly performance and the provided guidance of mid-single-digit organic growth for the fiscal year 2025. The company's ability to sustain its current momentum and execute effectively was noted, with UBS conceding that continued success could potentially challenge their cautious stance.

The analyst from UBS summarized their position, stating that while Medtronic has delivered a solid quarter with sales and EPS upside, they remain skeptical about the longevity of the new product momentum. They also suggested that the consensus EPS for fiscal year 2025 might be set too high, considering the various financial challenges outlined by the company's management.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.